Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs Under Armour Inc Class A — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.59 (market cap $2.27B), while Under Armour Inc Class A trades at $4.81 (market cap $2.07B). The key difference: SELLAS Life Sciences Group Inc. Common Stock and Under Armour Inc Class A are close in size by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| SLS | UA | |
|---|---|---|
Market Cap | $2.27B | $2.07B |
Volume | 4,179,659 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.46 | $7.88 |
52-Week Low | $1.39 | $3.96 |
Enterprise Value | $2.14B | $3.05B |
Typical Hold Time | — | 18 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Under Armour (UA) trades at $4.75, up 1.06% with a bullish technical signal despite mixed earnings. The company reported Q2 2026 EPS beat but faces revenue declines and negative profitability metrics, including a -9.99% net income margin. Cash flow remains negative at -$362M for 2025, while analyst consensus shows 40% buy ratings amid ongoing operational challenges.
Outlook remains cautious with revenue guidance cuts and competitive pressures. Investment opportunity exists if turnaround strategies succeed, but risks include sustained negative cash flow, weak consumer demand, and high debt levels. The stock's low P/S ratio of 0.41 offers value potential if management can stabilize operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
